MissionIR's  Instablog

Send Message
We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices. It is our unwavering commitment to connect the investment community with companies that have great potential and a strong dedication to... More
My company:
My blog:
MissionIR Blog
  • BG Medicine, Inc. (BGMD) To Present On Galectin-3 At 2012 American Heart Association Meeting 0 comments
    Nov 5, 2012 5:42 PM | about stocks: BGMD

    BG Medicine is a life sciences company focused on the discovery, development, and commercialization of novel cardiovascular diagnostics. The company's first commercial product, the BGM Galectin-3 Test, is for use in patients with heart failure and is available in both the United States and Europe.

    The company announced today that it will be launching a major initiative to help hospitals reduce the number of unplanned readmissions for heart failure patients. The initiative will begin at the American Heart Association Scientific Sessions 2012 taking place November 3-7 in Los Angeles. Representatives at the BG Medicine booth (#1737) will be there to highlight the role that Galectin-3 blood testing can play in helping the medical community address the urgent need to reduce hospital readmission rates.

    Currently, even with optimal care, nearly a one-fourth of all Medicare heart failure patients are readmitted to the hospital within 30 days. This makes heart failure a major factor of hospital readmission rates, far ahead of heart attack and pneumonia. Because heart failure patients with elevated galectin-3 levels are two-to-three times more likely to be readmitted within 30 days to a hospital, identifying these high risk patients through galectin-3 testing is a potentially valuable and cost-effective in combating these readmissions.

    BG Medicine believes the company will benefit and be able to grow the market for its Galectin-3 Test thanks to recent government rulings. Effective October 1, 2012, new rules from the federal Centers for Medicare & Medicaid Services have made reducing unplanned hospital readmissions a critical priority. Hospitals that exceed the Medicare thresholds will be assessed financial penalties that may reach $1 billion by 2015, if improvements are not made.

    For additional information about BG Medicine and its Galectin-3 Test, visit www.bg-medicine.com

    Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

    Stocks: BGMD
Back To MissionIR's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.